EMEA-001672-PIP01-14 - paediatric investigation plan
varicella-zoster virus (live, attenuated)
PIPHuman
Finnish is available via eTranslation, the European Commission's machine translation service.
Translate to Finnish | Important information about machine translation
Key facts
- Invented name
- Zostavax
- Copalia
- Active substance
- varicella-zoster virus (live, attenuated)
- Therapeutic area
- Vaccines
- Decision number
- P/0309/2014
- PIP number
- EMEA-001672-PIP01-14
- Pharmaceutical form(s)
- Powder and solvent for suspension for injection
- Route(s) of administration
- Subcutaneous use
- Intramuscular use
- Contact for public enquiries
Sanofi Pasteur MSD SNC
France
E-mail: cbesnard@spmsd.com
Tel. +33 437284723
Fax +1 2673056450 / +1 7325944950- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date
- Compliance check done
- Ei